Strong cash flows projected in GILD stock forecast allow for sustained share buybacks, potentially lifting per-share earnings. Buy-side analysts highlight low beta, reducing systemic market risk. Morgan Stanley Maintains Buy on Gilead Sciences ( GILD ) The Liver Disease portfolio sales, which include chronic HCV, chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV), decreased 4% to $795 million in the second quarter. GILD stock forecast for FY2024 anticipates EPS beating consensus by 2–3%, bolstered by disciplined cost management. Balance sheet strength remains a differentiator in volatile biotech trade cycles.
